Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 3/20 | 0.50 |
| ▸ | RHOA | P61586 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088384 | 0.90 | LMNA (0.50) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL15844868 | 0.78 | HTR2C (0.51) | P2RX1LMNAKMT2ATACR1 | |
| SCHEMBL1445331 | 0.78 | LMNA (0.55) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL10799970 | 0.77 | RHOC (0.53) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL25522941 | 0.75 | RHOC (0.51) | RHOCRHOAMAPTGPR35MEN1 | |
| SCHEMBL10800301 | 0.73 | LMNA (0.56) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL10800557 | 0.73 | LMNA (0.56) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL20094557 | 0.73 | KDR (0.51) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL20094229 | 0.73 | KDR (0.51) | RHOCRHOAMAPTGPR35P2RX1 | |
| SCHEMBL20094558 | 0.73 | KDR (0.51) | RHOCRHOAMAPTGPR35P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | RHOC 3979/4885RHOA 2777/4885MAPT 3509/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | RHOC 3979/4885RHOA 2777/4885MAPT 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.